Evidence map›Paper›PMID 41097394›Full record

ArticleMolecules (Basel, Switzerland)2025

Detection of Biomarker Clusterin in SERS Immunoassays on Al Foil After Substrate Selection and Assay Optimization with Fluorescently Labeled Antibodies.

Saule Mergenbayeva, Xeniya Terzapulo, Rostislav Bukasov

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Saule MergenbayevaDepartment of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-3110-5396
Xeniya TerzapuloDepartment of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0009-0002-4490-2551
Rostislav BukasovDepartment of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-7060-1632

Funding

Nazarbayev University Research Administration 20122022FD4140.
6 · The paper itself

Abstract

Clusterin plays an important role in carcinogenesis and serves as an important diagnostic biomarker of various clinical conditions. This work describes an application of a surface-enhanced Raman scattering (SERS)-based immunoassay using Al foil substrate that has the potential for the detection of clusterin. We first optimized the parameters of the assay using anti-human IgG/human IgG (hIgG) as a model antibody/antigen system using various substrates based on Au film, Si, Al tape and Al foil. Among the tested substrates, Al foil exhibited better performance, when assay of human IgG on Al foil demonstrated a detection limit of 2 pM and a semi logarithmic trend range from 10 pM to 1000 pM. Afterwards, the same SERS immunoassay method was implemented for detection of clusterin and resulted in a good semi-logarithmic calibration line with a high R

Indexed as

AluminumAntibodiesBiomarkersClusterinFluorescent DyesSpectrum Analysis, RamanGoldHumansImmunoassayImmunoglobulin GLimit of DetectionAluminumAntibodiesBiomarkersClusterinFluorescent DyesGoldImmunoglobulin Galuminum foilclusterinLODSERS immunoassaysSERS substratessurface-enhanced Raman spectroscopy (SERS)

Identifiers

PMID41097394
PMCPMC12525947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.